Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10588740
Filing Date		2006-08-04
First Named Inventor	Jose	Hermida Santos
Art Unit		1645
Examiner Name		
Attorney Docket Numb	er	020884-000011

				•					
				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines whe nt Passages or Rel s Appear	
	1	6037450	A	2000-03-14	Esmon et al.				
	2	6617145	B2	2003-09-09	Boone et al.				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant Relev		Releva	Columns,Lines whe nt Passages or Rel s Appear	
lf you wis	h to a	dd additional U.S. Publ	ished Ap	plication citatio		•	d button	Add	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	70
	1	0600088	EP	A1	1994-06-08	Koike et al.			[
If you wis	h to a	dd additional Foreign F	atent Do	cument citation	information p	lease click the Add	button	Add	_
			NO	-PATENT LITE	DATURE DO	CUMENTS		Remove	

#### 

Examiner Initials*	Cite No		L LETTERS), title of the article (when appropriate), title of the item sium, catalog, etc), date, pages(s), volume-issue number(s), Dished.
	1		ies Directed Agamst a Combination of Phospholipids with Prothrombin, Their Pathogenic Mechanism?" Blood. Mayo, Vol. 81, No. 10, (1993), pp.
	2		III Protein C Receptor Gene in Mice Causes Placental Thrombosis and Biological Chemistry, Vol. 277, No. 45, (2002), pp. 43335-43343.
If you wis	h to a	d additional non-patent literature docum	ent citation information please click the Add button Add
		EXA	MINER SIGNATURE
Examiner	Signa	ture	Date Considered

1 See Kind Codes of USPTO Patent Documents at year LISPTO\_CODE or MPEP 901.6.2 Enter office that issued the document, by the holdest code (WIPO Standard ST.3). Story duplement patent columents, by making on the year of the Emperor must precede the serial number of the period ocument, by making of the Emperor must precede the serial number of the period colument, and the control of the serial number of the period colument, and the serial number of the period ocument, and the serial number of the period colument.

\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if Emplish Engingues the relation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10588740	
Filing Date		2006-08-04	
First Named Inventor	Jose Hermida Santos		
Art Unit		1645	
Examiner Name			
Attorney Docket Numb	er	020884-000011	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s	s):
---------------	----------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Tristan A. Fuierer

Name/Print

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

52.926

Tomas or and origination			
Signature	/Tristan A. Fuierer/	Date (YYYY-MM-DD)	2006-11-20

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.